Tudor Investment Corp ET AL Purchases New Shares in Twist Bioscience Corporation $TWST

Tudor Investment Corp ET AL purchased a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 25,465 shares of the company’s stock, valued at approximately $717,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Quarry LP purchased a new stake in Twist Bioscience during the 3rd quarter valued at $28,000. Smartleaf Asset Management LLC grew its position in Twist Bioscience by 70.6% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,068 shares of the company’s stock valued at $29,000 after acquiring an additional 442 shares during the last quarter. National Bank of Canada FI bought a new position in Twist Bioscience in the 3rd quarter valued at $46,000. Geneos Wealth Management Inc. bought a new position in Twist Bioscience in the 2nd quarter valued at $97,000. Finally, CWM LLC grew its position in Twist Bioscience by 61.4% in the 3rd quarter. CWM LLC now owns 4,331 shares of the company’s stock valued at $122,000 after acquiring an additional 1,648 shares during the last quarter.

Insider Buying and Selling

In other Twist Bioscience news, Director Robert Chess sold 10,000 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $47.00, for a total value of $470,000.00. Following the completion of the sale, the director directly owned 21,084 shares in the company, valued at approximately $990,948. This trade represents a 32.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Melissa A. Starovasnik sold 1,000 shares of the stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $51.00, for a total value of $51,000.00. Following the completion of the sale, the director owned 25,722 shares of the company’s stock, valued at approximately $1,311,822. This trade represents a 3.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 46,049 shares of company stock valued at $2,198,717 in the last 90 days. 3.08% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have commented on the company. Guggenheim upped their price objective on Twist Bioscience from $50.00 to $55.00 and gave the company a “buy” rating in a research report on Monday, March 30th. Barclays increased their price target on Twist Bioscience from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday. Robert W. Baird set a $50.00 price target on Twist Bioscience in a research report on Tuesday, February 3rd. TD Cowen reissued a “buy” rating on shares of Twist Bioscience in a research report on Thursday, January 8th. Finally, Evercore increased their price target on Twist Bioscience from $42.00 to $52.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.13.

Twist Bioscience Price Performance

Shares of TWST stock opened at $57.41 on Wednesday. Twist Bioscience Corporation has a 1-year low of $23.30 and a 1-year high of $59.00. The stock’s 50-day moving average is $48.07 and its 200 day moving average is $38.59. The company has a market cap of $3.52 billion, a P/E ratio of -44.85 and a beta of 2.20. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.78 and a quick ratio of 3.37.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative net margin of 19.56% and a negative return on equity of 27.16%. The company had revenue of $103.70 million for the quarter, compared to the consensus estimate of $100.32 million. The firm’s quarterly revenue was up 16.9% compared to the same quarter last year. Research analysts predict that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.